Expanded Access for CC-486

APPROVED_FOR_MARKETING

Conditions studied: Acute Myelogenous Leukemia (AML)

In brief

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.

Key facts

Study ID

NCT03723135

Run by

Celgene

Last updated by the study team

2020-09-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients with documented acute myelogenous leukemia (AML) in their first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, who seek treatment with CC-486 as monotherapy to maintain their CR or CRi.

You may not qualify if…

• Patients with AML in CR/CRi who plan to proceed to or are waiting for a bone marrow transplant
• Patients who have received a bone marrow transplant for the treatment of AML
• Treatment of AML patients with relapse or refractory disease
• Pregnant or breast-feeding females
• Patient meets enrollment criteria and can participate in a disease-specific clinical trial

Where it is running

• Celgene — Summit, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.